Alivus Life Sciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Results
Alivus Life Sciences share price Rs 1,416.20 on 9 September 2026, up 3.22%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 160.00 crore. Q2 FY26 base a profit of Rs 130.00 crore.
Quick Answer
The Alivus Life Sciences Q2 results date for FY27 is not confirmed, and Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 588.00 crore in revenue and a profit of Rs 130.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Alivus Life Sciences Q2 results FY27 announcement is the next scheduled earnings event for Alivus Life Sciences Ltd., an active pharmaceutical ingredients maker, formerly listed as Glenmark Life Sciences, supplying regulated and emerging markets alongside a contract development and manufacturing business. The stock traded at Rs 1,416.20 on the NSE on 9 September 2026, up 3.22% from the previous close of Rs 1,372.00, about 5.2% below its 52-week high of Rs 1,493.80 and 72.9% above its 52-week low of Rs 819.00.
What makes the Alivus Life Sciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 588.00 crore of revenue and a profit of Rs 130.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 640.00 crore and a profit of Rs 160.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Alivus Life Sciences Q2 Results FY27 Date?
The Alivus Life Sciences Q2 results date for FY27 is not confirmed. As of 9 September 2026, Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Alivus Life Sciences Q2 results date becomes public through that filing rather than through any advance announcement.
The Alivus Life Sciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Alivus Life Sciences.
Alivus Life Sciences Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Alivus Life Sciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Alivus Life Sciences. The Alivus Life Sciences Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is the steady margin improvement. Operating margin reached 33% in Q1 FY27 against 30% in the September 2025 quarter, and that has carried profit from Rs 130 crore to Rs 160 crore even though revenue was slightly higher rather than dramatically so.
The second is the active ingredients order pattern. Supply to regulated market customers arrives in campaigns, which is why revenue moved between Rs 588 crore and Rs 689 crore across five quarters without a clear trend.
The third is the contract development and manufacturing business. That segment carries different economics from the base active ingredients portfolio, and its growth is what would lift margin structurally rather than cyclically.
Check Alivus Life Sciences Ltd. Live Fundamentals on the Univest Screener
Alivus Life Sciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Alivus Life Sciences Ltd. reported revenue of Rs 640.00 crore in Q1 FY27, up 6.31% from Rs 602.00 crore in Q1 FY26, and a profit of Rs 160.00 crore at the net level, up 31.15% from Rs 122.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 7.11% over the March 2026 quarter figure of Rs 689.00 crore, and net profit was down 1.84% from Rs 163.00 crore in Q4 FY26. Operating margin stood at 33.0% in Q1 FY27 against 30.0% in the September 2025 quarter, which is the comparison the Alivus Life Sciences Q2 results print will be read against.
Q2 FY26 Base: The Comparison Alivus Life Sciences Q2 Results FY27 Must Beat
Alivus Life Sciences Ltd. reported revenue of Rs 588.00 crore and a profit of Rs 130.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Alivus Life Sciences Q2 results preview.
Net profit in that base quarter was below the Rs 160.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 588.00 crore sits below the Rs 640.00 crore of the June 2026 quarter, which frames how much sequential movement the Alivus Life Sciences Q2 results print needs to show growth.
Alivus Life Sciences Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 588.00 | 130.00 |
| Q3 FY26 (Dec 2025) | 673.00 | 150.00 |
| Q4 FY26 (Mar 2026) | 689.00 | 163.00 |
| Q1 FY27 (Jun 2026) | 640.00 | 160.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Alivus Life Sciences Q2 results preview uses.
Revenue across those four quarters ranged from Rs 588.00 crore to Rs 689.00 crore, and net profit from Rs 130.00 crore to Rs 163.00 crore. That spread is the honest context for the Alivus Life Sciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Alivus Life Sciences Q2 Results FY27
The Alivus Life Sciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Alivus Life Sciences has already reported.
Regulated Market Supply
Selling active ingredients into regulated markets requires plant approvals and customer qualification. Any inspection outcome disclosed with results affects the addressable revenue for several quarters ahead.
Name Change From Glenmark Life Sciences
The company was formerly listed as Glenmark Life Sciences and several data sources still carry that name. Figures for the same period can appear under either label, which matters when comparing across sources.
Strong Returns and a Strong Run
Alivus Life Sciences generates a return on equity of 17.90% with a debt-to-equity ratio of 0.12, and trades at a price-to-earnings ratio of 27.96 against a sector average of 37.99. The stock has risen from a 52-week low of Rs 819.00 to near its high of Rs 1,493.80.
Alivus Life Sciences Q2 Results FY27: Share Price and Valuation Going Into the Print
Alivus Life Sciences share price today is Rs 1,416.20 on the NSE, up Rs 44.20 or 3.22% from the previous close of Rs 1,372.00 on 9 September 2026, ahead of the Alivus Life Sciences Q2 results announcement.
| Metric | Value (8 September 2026) |
|---|---|
| NSE Symbol | ALIVUS |
| Current Market Price | Rs 1,416.20 |
| 52-Week High | Rs 1,493.80 |
| 52-Week Low | Rs 819.00 |
| Market Capitalisation | Rs 16,863 crore |
| PE Ratio | 27.96 |
| Sector PE | 37.99 |
| PB Ratio | 5.22 |
| EPS (TTM) | Rs 50.65 |
| Book Value per Share | Rs 271.00 |
| Debt to Equity | 0.12 |
| Return on Equity | 17.90% |
| 50-Day Moving Average | Rs 1,267.70 |
| 200-Day Moving Average | Rs 1,045.84 |
| RSI (14) | 56.64 |
The stock trades above both its 50-day average of Rs 1,267.70 and its 200-day average of Rs 1,045.84, with a 14-day RSI of 56.64. None of this is a view on where the shares go once the Alivus Life Sciences Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Alivus Life Sciences Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Alivus Life Sciences Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Alivus Life Sciences Q2 results print in proportion.
- Revenue against the Rs 588.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 130.00 crore in that same quarter
- Operating margin against 33.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Alivus Life Sciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Alivus Life Sciences Q2 Results FY27
The Alivus Life Sciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Alivus Life Sciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Alivus Life Sciences Q2 results FY27 print faces a base of Rs 588.00 crore in revenue and a profit of Rs 130.00 crore, with the most recent quarter having delivered Rs 640.00 crore and a profit of Rs 160.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Alivus Life Sciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Alivus Life Sciences Q2 Results FY27
What is the Alivus Life Sciences Q2 results date for FY27?
Ans. The Alivus Life Sciences Q2 results date for FY27 is not confirmed. Alivus Life Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Alivus Life Sciences Q2 results 2026 cover?
Ans. The Alivus Life Sciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Alivus Life Sciences Ltd. reports revenue, operating profit and net profit for that period, and the Alivus Life Sciences Q2 results filing also carries the notes to the accounts.
What were the Alivus Life Sciences Q1 FY27 results?
Ans. Alivus Life Sciences Ltd. reported revenue of Rs 640.00 crore in Q1 FY27 and a profit of Rs 160.00 crore at the net level. Revenue was up 6.31% versus Q1 FY26 and net profit was up 31.15% from Rs 122.00 crore in Q1 FY26.
What were Alivus Life Sciences Q2 FY26 results in the September 2025 quarter?
Ans. Alivus Life Sciences Ltd. reported revenue of Rs 588.00 crore and a profit of Rs 130.00 crore in Q2 FY26. Operating margin was 30.0%. Those figures form the base for the Alivus Life Sciences Q2 results FY27 comparison.
What are the main Alivus Life Sciences Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Alivus Life Sciences Q2 results expectations centre on revenue against the Rs 588.00 crore base, net profit against a profit of Rs 130.00 crore, operating margin against 33.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Alivus Life Sciences share price today ahead of the Q2 earnings?
Ans. Alivus Life Sciences share price is Rs 1,416.20 on the NSE as of 9 September 2026, up 3.22% from Rs 1,372.00. The stock is about 5.2% below its 52-week high of Rs 1,493.80 and 72.9% above its 52-week low of Rs 819.00, at a market capitalisation of Rs 16,863 crore.
Is Alivus Life Sciences a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Alivus Life Sciences Ltd.. The stock trades at a price-to-book ratio of 5.22 with a return on equity of 17.90%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
